

May 10, 2019

U Mass - Chronic/acute phloridzin treatment

DOI

dx.doi.org/10.17504/protocols.io.xujfnun



Jason Kim¹

¹University of Massachusetts

Mouse Metabolic Phenotyping Centers
Tech. support email: info@mmpc.org



Lili Liang

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.xujfnun>

External link: <https://mmpc.org/shared/document.aspx?id=154&docType=Protocol>

Protocol Citation: Jason Kim 2019. U Mass - Chronic/acute phloridzin treatment. **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.xujfnun>

License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: February 06, 2019

Last Modified: May 10, 2019

Protocol Integer ID: 20075

Keywords: Phloridzin, diabetic mice, acute phloridzin treatment summary, potent inhibitor of renal glucose reabsorption, phloridzin, renal glucose reabsorption, potent inhibitor, glucose, serum glucose levels for experiment, glycosuria, lower hyperglycemia in diabetic mice, serum glucose level, hyperglycemia, lower hyperglycemia


Abstract

Summary:

Phloridzin is a potent inhibitor of renal glucose reabsorption and may be used to lower serum glucose levels. Phloridzin may be administered chronically to induce glycosuria and lower hyperglycemia in diabetic mice. Phloridzin may be administered acutely to reduce serum glucose levels for experiments in diabetic mice.

Materials

MATERIALS

 Phloridzin **Merck MilliporeSigma (Sigma-Aldrich) Catalog #P3449**

 Osmotic pump **Alzet Catalog #1007D**

Note:

Sigma-Aldrich, [RRID:SCR_008988](#)

Troubleshooting

1 **For chronic phloridzin treatment:**

1. Anesthetize mice with an intraperitoneal injection of ketamine (100 mg/kg body weight) and xylazine (10 mg/kg body weight).
2. Shave hair at the incision site on the back.
3. Make an incision (~0.5 cm) using sterilized scalpel between the scapulae.
4. Subcutaneously insert an Alzet mouse osmotic pump containing phloridzin (0.4 mg/kg body weight).
5. Suture or close the incision site using sterilized staples.
6. Administer ketoprofen to minimize pain and house mice individually.
7. Alternatively, phloridzin may be chronically administered using a twice daily intraperitoneal injection at 0.4 mg/kg body weight.

2 **For acute phloridzin treatment:**

1. Survival surgery is performed to establish a chronic indwelling catheter at 5~6 days prior to experiment for intravenous infusion. (refer to M1023: Surgery-jugular vein cannulation)
2. Mice are fasted overnight (~15 hours) or for 5 hours prior to the start of experiment.
3. Place a mouse in a rat-size restrainer with its tail tape-tethered at one end.
4. Expose and flush the intravenous catheter using saline solution. Then, connect the catheter to the CMA Microdialysis infusion pump.
5. Phloridzin is intravenously infused at 100 μ g/kg/min for 60~120 min to lower serum glucose levels in hyperglycemic, diabetic mice.